{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T21:09:50Z","timestamp":1791407390123,"version":"4.3.3"},"reference-count":25,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2022,1,19]],"date-time":"2022-01-19T00:00:00Z","timestamp":1642550400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2022,1,19]],"date-time":"2022-01-19T00:00:00Z","timestamp":1642550400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/100000005","name":"U.S. Department of Defense","doi-asserted-by":"publisher","award":["W81XWH-13-2-0065"],"award-info":[{"award-number":["W81XWH-13-2-0065"]}],"id":[{"id":"10.13039\/100000005","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Neuropsychopharmacol."],"published-print":{"date-parts":[[2022,7]]},"DOI":"10.1038\/s41386-022-01266-9","type":"journal-article","created":{"date-parts":[[2022,1,19]],"date-time":"2022-01-19T03:03:04Z","timestamp":1642561384000},"page":"1574-1581","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":104,"title":["Dose-related effects of ketamine for antidepressant-resistant symptoms of posttraumatic stress disorder in veterans and active duty military: a double-blind, randomized, placebo-controlled multi-center clinical trial"],"prefix":"10.1038","volume":"47","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5783-6181","authenticated-orcid":false,"given":"Chadi G.","family":"Abdallah","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John D.","family":"Roache","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ralitza","family":"Gueorguieva","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lynnette A.","family":"Averill","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stacey","family":"Young-McCaughan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paulo R.","family":"Shiroma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Prerana","family":"Purohit","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antoinette","family":"Brundige","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William","family":"Murff","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kyung-Heup","family":"Ahn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohamed A.","family":"Sherif","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric J.","family":"Baltutis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohini","family":"Ranganathan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3141-1462","authenticated-orcid":false,"given":"Deepak","family":"D\u2019Souza","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brenda","family":"Martini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steven M.","family":"Southwick","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ismene L.","family":"Petrakis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rebecca R.","family":"Burson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kevin B.","family":"Guthmiller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Argelio L.","family":"L\u00f3pez-Roca","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karl A.","family":"Lautenschlager","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"suffix":"III","given":"John P.","family":"McCallin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew B.","family":"Hoch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexandar","family":"Timchenko","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sergio E.","family":"Souza","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charles E.","family":"Bryant","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jim","family":"Mintz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brett T.","family":"Litz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Douglas E.","family":"Williamson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Terence M.","family":"Keane","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alan L.","family":"Peterson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6952-1726","authenticated-orcid":false,"given":"John H.","family":"Krystal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,1,19]]},"reference":[{"key":"1266_CR1","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1146\/annurev-pharmtox-010818-021701","volume":"59","author":"CG Abdallah","year":"2019","unstructured":"Abdallah CG, Averill LA, Akiki TJ, Raza M, Averill CL, Gomaa H, et al. The neurobiology and pharmacotherapy of posttraumatic stress disorder. Annu Rev Pharm Toxicol. 2019;59:171\u201389. https:\/\/doi.org\/10.1146\/annurev-pharmtox-010818-021701.","journal-title":"Annu Rev Pharm Toxicol"},{"key":"1266_CR2","doi-asserted-by":"publisher","first-page":"2459","DOI":"10.1056\/NEJMra1612499","volume":"376","author":"A Shalev","year":"2017","unstructured":"Shalev A, Liberzon I, Marmar C. Post-traumatic stress disorder. N. Engl J Med. 2017;376:2459\u201369. https:\/\/doi.org\/10.1056\/NEJMra1612499.","journal-title":"N. Engl J Med"},{"key":"1266_CR3","doi-asserted-by":"publisher","first-page":"15057","DOI":"10.1038\/nrdp.2015.57","volume":"1","author":"R Yehuda","year":"2015","unstructured":"Yehuda R, Hoge CW, McFarlane AC, Vermetten E, Lanius RA, Nievergelt CM, et al. Post-traumatic stress disorder. Nat Rev Dis Prim. 2015;1:15057. https:\/\/doi.org\/10.1038\/nrdp.2015.57.","journal-title":"Nat Rev Dis Prim"},{"key":"1266_CR4","doi-asserted-by":"publisher","unstructured":"Akiki TJ, Abdallah CG. Are there effective psychopharmacologic treatments for PTSD? J Clin Psychiatry. 2018;80. https:\/\/doi.org\/10.4088\/JCP.18ac12473.","DOI":"10.4088\/JCP.18ac12473"},{"key":"1266_CR5","doi-asserted-by":"publisher","first-page":"e51","DOI":"10.1016\/j.biopsych.2017.03.007","volume":"82","author":"JH Krystal","year":"2017","unstructured":"Krystal JH, Davis LL, Neylan TC, M AR, Schnurr PP, Stein MB, et al. It is time to address the crisis in the pharmacotherapy of posttraumatic stress disorder: a consensus statement of the PTSD Psychopharmacology Working Group. Biol Psychiatry. 2017;82:e51\u2013e9. https:\/\/doi.org\/10.1016\/j.biopsych.2017.03.007.","journal-title":"Biol Psychiatry"},{"key":"1266_CR6","doi-asserted-by":"publisher","unstructured":"Cipriani A, Williams T, Nikolakopoulou A, Salanti G, Chaimani A, Ipser J, et al. Comparative efficacy and acceptability of pharmacological treatments for post-traumatic stress disorder in adults: a network meta-analysis. Psychol Med. 2017:1\u201310. https:\/\/doi.org\/10.1017\/S003329171700349X.","DOI":"10.1017\/S003329171700349X"},{"key":"1266_CR7","doi-asserted-by":"publisher","first-page":"e541","DOI":"10.4088\/JCP.12r08225","volume":"74","author":"BV Watts","year":"2013","unstructured":"Watts BV, Schnurr PP, Mayo L, Young-Xu Y, Weeks WB, Friedman MJ. Meta-analysis of the efficacy of treatments for posttraumatic stress disorder. J Clin Psychiatry. 2013;74:e541\u201350. https:\/\/doi.org\/10.4088\/JCP.12r08225.","journal-title":"J Clin Psychiatry"},{"key":"1266_CR8","doi-asserted-by":"publisher","first-page":"148","DOI":"10.1016\/j.pharmthera.2018.05.010","volume":"190","author":"CG Abdallah","year":"2018","unstructured":"Abdallah CG, Sanacora G, Duman RS, Krystal JH. The neurobiology of depression, ketamine and rapid-acting antidepressants: Is it glutamate inhibition or activation?. Pharm Ther. 2018;190:148\u201358. https:\/\/doi.org\/10.1016\/j.pharmthera.2018.05.010.","journal-title":"Pharm Ther"},{"key":"1266_CR9","doi-asserted-by":"publisher","unstructured":"Kraus C, Wasserman D, Henter ID, Acevedo-Diaz E, Kadriu B, Zarate CA Jr. The influence of ketamine on drug discovery in depression. Drug Discov Today. 2019. https:\/\/doi.org\/10.1016\/j.drudis.2019.07.007.","DOI":"10.1016\/j.drudis.2019.07.007"},{"key":"1266_CR10","doi-asserted-by":"publisher","first-page":"681","DOI":"10.1001\/jamapsychiatry.2014.62","volume":"71","author":"A Feder","year":"2014","unstructured":"Feder A, Parides MK, Murrough JW, Perez AM, Morgan JE, Saxena S, et al. Efficacy of intravenous ketamine for treatment of chronic posttraumatic stress disorder: a randomized clinical trial. JAMA psychiatry. 2014;71:681\u20138. https:\/\/doi.org\/10.1001\/jamapsychiatry.2014.62.","journal-title":"JAMA psychiatry"},{"key":"1266_CR11","doi-asserted-by":"publisher","unstructured":"Feder A, Costi S, Rutter SB, Collins AB, Govindarajulu U, Jha MK, et al. A randomized controlled trial of repeated ketamine administration for chronic posttraumatic stress disorder. Am J Psychiatry. 2021:appiajp202020050596. https:\/\/doi.org\/10.1176\/appi.ajp.2020.20050596.","DOI":"10.1176\/appi.ajp.2020.20050596"},{"key":"1266_CR12","doi-asserted-by":"publisher","unstructured":"Albott CS, Lim KO, Forbes MK, Erbes C, Tye SJ, Grabowski JG, et al. Efficacy, safety, and durability of repeated ketamine infusions for comorbid posttraumatic stress disorder and treatment-resistant depression. J Clin Psychiatry. 2018;79. https:\/\/doi.org\/10.4088\/JCP.17m11634.","DOI":"10.4088\/JCP.17m11634"},{"key":"1266_CR13","doi-asserted-by":"publisher","first-page":"247054702098068","DOI":"10.1177\/2470547020980681","volume":"4","author":"D Dai","year":"2020","unstructured":"Dai D, Lacadie CM, Holmes SE, Cool R, Anticevic A, Averill C, et al. Ketamine normalizes the structural alterations of inferior frontal gyrus in depression. Chronic Stress. 2020;4:2470547020980681.","journal-title":"Chronic Stress"},{"key":"1266_CR14","doi-asserted-by":"publisher","first-page":"247054702098167","DOI":"10.1177\/2470547020981670","volume":"4","author":"AR Dadabayev","year":"2020","unstructured":"Dadabayev AR, Joshi SA, Reda MH, Lake T, Hausman MS, Domino E, et al. Low dose ketamine infusion for comorbid posttraumatic stress disorder and chronic pain: a randomized double-blind clinical trial. Chronic Stress 2020;4:2470547020981670.","journal-title":"Chronic Stress"},{"key":"1266_CR15","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1016\/j.cct.2019.04.009","volume":"81","author":"CG Abdallah","year":"2019","unstructured":"Abdallah CG, Roache JD, Averill LA, Young-McCaughan S, Martini B, Gueorguieva R, et al. Repeated ketamine infusions for antidepressant-resistant PTSD: methods of a multicenter, randomized, placebo-controlled clinical trial. Contemp Clin Trials. 2019;81:11\u20138. https:\/\/doi.org\/10.1016\/j.cct.2019.04.009.","journal-title":"Contemp Clin Trials"},{"key":"1266_CR16","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1097\/PRA.0000000000000091","volume":"21","author":"J Guina","year":"2015","unstructured":"Guina J, Rossetter SR, De RB, Nahhas RW, Welton RS. Benzodiazepines for PTSD: a systematic review and meta-analysis. J Psychiatr Pr. 2015;21:281\u2013303. https:\/\/doi.org\/10.1097\/PRA.0000000000000091.","journal-title":"J Psychiatr Pr"},{"key":"1266_CR17","doi-asserted-by":"publisher","first-page":"1592","DOI":"10.1038\/s41380-018-0256-5","volume":"25","author":"M Fava","year":"2020","unstructured":"Fava M, Freeman MP, Flynn M, Judge H, Hoeppner BB, Cusin C, et al. Double-blind, placebo-controlled, dose-ranging trial of intravenous ketamine as adjunctive therapy in treatment-resistant depression (TRD). Mol Psychiatry. 2020;25:1592\u2013603. https:\/\/doi.org\/10.1038\/s41380-018-0256-5.","journal-title":"Mol Psychiatry"},{"key":"1266_CR18","doi-asserted-by":"publisher","first-page":"2482","DOI":"10.1038\/npp.2017.94","volume":"42","author":"TP Su","year":"2017","unstructured":"Su TP, Chen MH, Li CT, Lin WC, Hong CJ, Gueorguieva R, et al. Dose-related effects of adjunctive ketamine in taiwanese patients with treatment-resistant depression. Neuropsychopharmacology. 2017;42:2482\u201392. https:\/\/doi.org\/10.1038\/npp.2017.94.","journal-title":"Neuropsychopharmacology"},{"key":"1266_CR19","doi-asserted-by":"publisher","first-page":"816","DOI":"10.1176\/appi.ajp.2016.16010037","volume":"173","author":"JB Singh","year":"2016","unstructured":"Singh JB, Fedgchin M, Daly EJ, De Boer P, Cooper K, Lim P, et al. A double-blind, randomized, placebo-controlled, dose-frequency study of intravenous ketamine in patients with treatment-resistant depression. Am J Psychiatry. 2016;173:816\u201326. https:\/\/doi.org\/10.1176\/appi.ajp.2016.16010037.","journal-title":"Am J Psychiatry"},{"key":"1266_CR20","doi-asserted-by":"publisher","unstructured":"Duek O, Spiller TR, Pietrzak RH, Fried EI, Harpaz-Rotem I. Network analysis of PTSD and depressive symptoms in 158,139 treatment-seeking veterans with PTSD. Depress Anxiety. 2020. https:\/\/doi.org\/10.1002\/da.23112.","DOI":"10.1002\/da.23112"},{"key":"1266_CR21","doi-asserted-by":"publisher","unstructured":"Schiavone FL, McKinnon MC, Lanius RA. Psychotic-like symptoms and the temporal lobe in trauma-related disorders: diagnosis, treatment, and assessment of potential malingering. Chronic Stress (Thousand Oaks). 2018;2. https:\/\/doi.org\/10.1177\/2470547018797046.","DOI":"10.1177\/2470547018797046"},{"key":"1266_CR22","doi-asserted-by":"publisher","unstructured":"Mohamed S, Johnson GR, Sevilimedu V, Rao SD, Hicks PB, Chen P, et al. Impact of concurrent posttraumatic stress disorder on outcomes of antipsychotic augmentation for major depressive disorder with a prior failed treatment: VAST-D Randomized Clinical Trial. J Clin Psychiatry. 2020;81. https:\/\/doi.org\/10.4088\/JCP.19m13038.","DOI":"10.4088\/JCP.19m13038"},{"key":"1266_CR23","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1001\/archpsyc.1994.03950030035004","volume":"51","author":"JH Krystal","year":"1994","unstructured":"Krystal JH, Karper LP, Seibyl JP, Freeman GK, Delaney R, Bremner JD, et al. Subanesthetic effects of the noncompetitive NMDA antagonist, ketamine, in humans. Psychotomimetic, perceptual, cognitive, and neuroendocrine responses. Arch Gen Psychiatry. 1994;51:199\u201314.","journal-title":"Arch Gen Psychiatry"},{"key":"1266_CR24","doi-asserted-by":"publisher","first-page":"1134","DOI":"10.1176\/appi.ajp.2013.13030392","volume":"170","author":"JW Murrough","year":"2013","unstructured":"Murrough JW, Iosifescu DV, Chang LC, Al Jurdi RK, Green CE, Perez AM, et al. Antidepressant efficacy of ketamine in treatment-resistant major depression: a two-site randomized controlled trial. Am J Psychiatry. 2013;170:1134\u201342. https:\/\/doi.org\/10.1176\/appi.ajp.2013.13030392.","journal-title":"Am J Psychiatry"},{"key":"1266_CR25","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1159\/000069738","volume":"72","author":"M Fava","year":"2003","unstructured":"Fava M, Evins AE, Dorer DJ, Schoenfeld DA. The problem of the placebo response in clinical trials for psychiatric disorders: culprits, possible remedies, and a novel study design approach. Psychother Psychosom. 2003;72:115\u201327. https:\/\/doi.org\/10.1159\/000069738.","journal-title":"Psychother Psychosom"}],"updated-by":[{"DOI":"10.1038\/s41386-022-01339-9","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2022,5,11]],"date-time":"2022-05-11T00:00:00Z","timestamp":1652227200000}}],"container-title":["Neuropsychopharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41386-022-01266-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41386-022-01266-9","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41386-022-01266-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,8]],"date-time":"2025-04-08T12:10:06Z","timestamp":1744114206000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41386-022-01266-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,1,19]]},"references-count":25,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2022,7]]}},"alternative-id":["1266"],"URL":"https:\/\/doi.org\/10.1038\/s41386-022-01266-9","relation":{"has-preprint":[{"id-type":"doi","id":"10.1101\/2021.04.30.21256273","asserted-by":"object"}]},"ISSN":["0893-133X","1740-634X"],"issn-type":[{"value":"0893-133X","type":"print"},{"value":"1740-634X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,1,19]]},"assertion":[{"value":"11 June 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 December 2021","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 December 2021","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 January 2022","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 May 2022","order":5,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Correction","order":6,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"A Correction to this paper has been published:","order":7,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"https:\/\/doi.org\/10.1038\/s41386-022-01339-9","URL":"https:\/\/doi.org\/10.1038\/s41386-022-01339-9","order":8,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Dr. Abdallah has served as a consultant, speaker and\/or on advisory boards for Aptinyx,\u00a0Genentech, Janssen, Psilocybin Labs, Lundbeck, Guidepoint, and FSV7, and as editor of Chronic Stress for Sage Publications, Inc. He also filed a patent for using mTORC1 inhibitors to augment the effects of antidepressants (Aug 20, 2018). Dr. Krystal is a consultant for Aptinyx, Inc., Atai Life Sciences, AstraZeneca Pharmaceuticals, Biogen, Idec, MA, Biomedisyn Corporation, Bionomics, Limited (Australia), Boehringer Ingelheim International, Cadent Therapeutics, Inc., Clexio Bioscience, Ltd., COMPASS Pathways, Limited, United Kingdom, Concert Pharmaceuticals, Inc., Epiodyne, Inc., EpiVario, Inc., Greenwich Biosciences, Inc., Heptares Therapeutics, Limited (UK), Janssen Research & Development, Jazz Pharmaceuticals, Inc., Otsuka America Pharmaceutical, Inc., Perception Neuroscience Holdings, Inc., Spring Care, Inc., Sunovion Pharmaceuticals, Inc., Takeda Industries, Taisho Pharmaceutical Co., Ltd. JHK also reports the following disclosures: Scientific Advisory Board: Biohaven Pharmaceuticals, BioXcel Therapeutics, Inc. (Clinical Advisory Board), Cadent Therapeutics, Inc. (Clinical Advisory Board), Cerevel Therapeutics, LLC, EpiVario, Inc., Eisai, Inc., Lohocla Research Corporation, Novartis Pharmaceuticals Corporation, PsychoGenics, Inc., RBNC Therapeutics, Inc., Tempero Bio, Inc., Terran Biosciences, Inc. Stock: Biohaven Pharmaceuticals, Sage Pharmaceuticals, Spring Care, Inc. Stock Options: Biohaven Pharmaceuticals Medical Sciences, EpiVario, Inc., RBNC Therapeutics, Inc., Terran Biosciences, Inc. Tempero Bio, Inc. Income Greater than $10,000: Editorial Board: Editor - Biological Psychiatry. Patents and Inventions: (1) Seibyl JP, Krystal JH, Charney DS Dopamine and noradrenergic reuptake inhibitors in treatment of schizophrenia. US Patent #:5,447,948.September 5, 1995. (2) Vladimir, Coric, Krystal, John H, Sanacora, Gerard \u2013 Glutamate Modulating Agents in the Treatment of Mental Disorders. US Patent No. 8,778,979 B2 Patent Issue Date: July 15, 2014. US Patent Application No. 15\/695,164: Filing Date: 09\/05\/2017. (3) Charney D, Krystal JH, Manji H, Matthew S, Zarate C., - Intranasal Administration of Ketamine to Treat Depression United States Patent Number: 9592207, Issue date: 3\/14\/2017. Licensed to Janssen Research & Development. (4) Zarate, C, Charney, DS, Manji, HK, Mathew, Sanjay J, Krystal, JH, Yale University \u201cMethods for Treating Suicidal Ideation\u201d, Patent Application No. 15\/379,013 filed on December 14, 2016 by Yale University Office of Cooperative Research. (5) Arias A, Petrakis I, Krystal JH. \u2013 Composition and methods to treat addiction. Provisional Use Patent Application no.61\/973\/961. April 2, 2014. Filed by Yale University Office of Cooperative Research. (6) Chekroud, A., Gueorguieva, R., & Krystal, JH. \u201cTreatment Selection for Major Depressive Disorder\u201d [filing date 3\n                      rd\n                      June 2016, USPTO docket number Y0087.70116US00]. Provisional patent submission by Yale University. (7) Gihyun, Yoon, Petrakis I, Krystal JH \u2013 Compounds, Compositions and Methods for Treating or Preventing Depression and Other Diseases. U. S. Provisional Patent Application No. 62\/444,552, filed on January10, 2017 by Yale University Office of Cooperative Research OCR 7088 US01. (8) Abdallah, C, Krystal, JH, Duman, R, Sanacora, G. Combination Therapy for Treating or Preventing Depression or Other Mood Diseases. U.S. Provisional Patent Application No. 62\/719,935 filed on August 20, 2018 by Yale University Office of Cooperative Research OCR 7451 US01. On Non-Federal Research Support: AstraZeneca Pharmaceuticals provides the drug, Saracatinib, for research related to NIAAA grant \u201cCenter for Translational Neuroscience of Alcoholism [CTNA-4] Novartis provides the drug, Mavoglurant, for research related to NIAAA grant \u201cCenter for Translational Neuroscience of Alcoholism [CTNA-4]. Dr. Gueorguieva discloses royalties from book \u201cStatistical Methods in Psychiatry and Related Fields\u201d published by CRC Press, honorarium as a member of the Working Group for PTSD Adaptive Platform Trial of Cohen Veterans Bioscience and a United States patent application 20200143922 by Yale University: Chekroud, A., Krystal, J., Gueorguieva, R. and Chandra, A. \u201cMethods and Apparatus for Predicting Depression Treatment Outcomes\u201d. Dr. Sherif is a consultant for In Silico Biosciences, Inc. Dr. Averill is a consultant for Guidepoint. All other co-authors declare no conflict of interest.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}